Abstract
Chemotherapeutic options for androgen-independent prostate cancer are extremely limited with minimum survival advantage. The benzyl-substituted unbridged titanocene bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) was tested in vitro against the human prostate cancer androgen-independent cell, PC-3, which demonstrated an IC50 value of 56 x 10-6 mol/L compared to 5.6 x 10-6 mol/L for cisplatin. Then Titanocene Y was given at the maximum tolerable dose of 40 mg/kg/d on five consecutive days to one cohort of eight PC3 tumor-bearing male NMRI:nu/nu mice, while a second cohort was treated similarly with 3 mg/kg/d of cisplatin. Both of these mouse cohorts showed a statistically significant tumor growth reduction with respect to the third solvent-treated control group, which led to T/C values of 42% for cisplatin and 52% for Titanocene Y at the end of the experiment. This encouraging activity of Titanocene Y against prostate tumors in vivo, which is almost comparable with respect to cisplatin hopefully leads to further development of Titanocene Y in the future.
Keywords: Anti-cancer drug, Cisplatin, Titanocene, Prostate Cancer, PC-3, Xenograft
Letters in Drug Design & Discovery
Title: Antitumor Activity of Titanocene Y in Xenografted PC3 Tumors in Mice
Volume: 5 Issue: 2
Author(s): Catherine M. Dowling, James Claffey, Sandra Cuffe, Iduna Fichtner, Clara Pampillon, Nigel J. Sweeney, Katja Strohfeldt, R. William G. Watson and Matthias Tacke
Affiliation:
Keywords: Anti-cancer drug, Cisplatin, Titanocene, Prostate Cancer, PC-3, Xenograft
Abstract: Chemotherapeutic options for androgen-independent prostate cancer are extremely limited with minimum survival advantage. The benzyl-substituted unbridged titanocene bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) was tested in vitro against the human prostate cancer androgen-independent cell, PC-3, which demonstrated an IC50 value of 56 x 10-6 mol/L compared to 5.6 x 10-6 mol/L for cisplatin. Then Titanocene Y was given at the maximum tolerable dose of 40 mg/kg/d on five consecutive days to one cohort of eight PC3 tumor-bearing male NMRI:nu/nu mice, while a second cohort was treated similarly with 3 mg/kg/d of cisplatin. Both of these mouse cohorts showed a statistically significant tumor growth reduction with respect to the third solvent-treated control group, which led to T/C values of 42% for cisplatin and 52% for Titanocene Y at the end of the experiment. This encouraging activity of Titanocene Y against prostate tumors in vivo, which is almost comparable with respect to cisplatin hopefully leads to further development of Titanocene Y in the future.
Export Options
About this article
Cite this article as:
Dowling M. Catherine, Claffey James, Cuffe Sandra, Fichtner Iduna, Pampillon Clara, Sweeney J. Nigel, Strohfeldt Katja, G. Watson William R. and Tacke Matthias, Antitumor Activity of Titanocene Y in Xenografted PC3 Tumors in Mice, Letters in Drug Design & Discovery 2008; 5 (2) . https://dx.doi.org/10.2174/157018008783928463
DOI https://dx.doi.org/10.2174/157018008783928463 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Complex Interactions between Phytochemicals. The Multi-Target Therapeutic Concept of Phytotherapy
Current Drug Targets AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy 2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Pharmaceutical Nanotechnology The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Titanocenes as Anticancer Agents: Recent Insights
Medicinal Chemistry The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology
Current Neuropharmacology Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Targeting Mitochondria: A New Promising Approach for the Treatment of Liver Diseases
Current Medicinal Chemistry Determination of Isoflavones in Legumes by QuEChERS-Capillary Electrophoresis-Electrospray Ionization-Mass Spectrometry
Current Analytical Chemistry Ion Transporters in Brain Tumors
Current Medicinal Chemistry Meet Our Editor
Current Metabolomics Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry Design of NAALADase Inhibitors A Novel Neuroprotective Strategy
Current Medicinal Chemistry Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy
Clinical Cancer Drugs The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets